230 related articles for article (PubMed ID: 9758315)
21. Liposomal drug delivery system from laboratory to clinic.
Kshirsagar NA; Pandya SK; Kirodian GB; Sanath S
J Postgrad Med; 2005; 51 Suppl 1():S5-15. PubMed ID: 16519249
[TBL] [Abstract][Full Text] [Related]
22. [Acute adverse effects following administration of liposomal amphotericin B].
Portillo-Cano Mdel M; Lobo-Acosta MA; Ríos-Villegas MJ; Alanís-López J
Enferm Infecc Microbiol Clin; 2006 May; 24(5):352. PubMed ID: 16762265
[No Abstract] [Full Text] [Related]
23. [Generalised toxicoderma secondary to administering liposomal amphotericin B].
de Miguel-Bouzas JC; Herrero-Poch L; Piñeiro-Corrales G
Farm Hosp; 2010; 34(4):211-2. PubMed ID: 20638033
[No Abstract] [Full Text] [Related]
24. Triad of acute infusion-related reactions associated with liposomal amphotericin B: analysis of clinical and epidemiological characteristics.
Roden MM; Nelson LD; Knudsen TA; Jarosinski PF; Starling JM; Shiflett SE; Calis K; DeChristoforo R; Donowitz GR; Buell D; Walsh TJ
Clin Infect Dis; 2003 May; 36(10):1213-20. PubMed ID: 12746764
[TBL] [Abstract][Full Text] [Related]
25. Assessment of nephrotoxicity of high-cumulative dose of liposomal amphotericin B in a pediatric patient who underwent allogeneic bone marrow transplantation.
Cesaro S; Zignol M; Burlina AB; Tridello G; Visintin G; Messina C
Pediatr Transplant; 2006 Mar; 10(2):255-8. PubMed ID: 16573618
[TBL] [Abstract][Full Text] [Related]
26. Liposomal amphotericin (AmBisome) is safe in bone marrow transplantation for primary immunodeficiency.
Pasic S; Flannagan L; Cant AJ
Bone Marrow Transplant; 1997 Jun; 19(12):1229-32. PubMed ID: 9208117
[TBL] [Abstract][Full Text] [Related]
27. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation.
El-Cheikh J; Faucher C; Fürst S; Duran S; Berger P; Vey N; Stoppa AM; Bouabdallah R; Gastaut JA; Viens P; Blaise D; Mohty M
Bone Marrow Transplant; 2007 Mar; 39(5):301-6. PubMed ID: 17262059
[TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of liposomal amphotericin B in patients with cryptococcal meningitis.
Kotwani RN; Gokhale PC; Bodhe PV; Kirodian BG; Kshirsagar NA
J Assoc Physicians India; 2001 Nov; 49():1086-90. PubMed ID: 11868862
[TBL] [Abstract][Full Text] [Related]
29. Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis.
Cordonnier C; Bresnik M; Ebrahimi R
Mycoses; 2007 May; 50(3):205-9. PubMed ID: 17472618
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
31. Caspofungin: new indication. No progress in invasive candidiasis.
Prescrire Int; 2004 Apr; 13(70):48-9. PubMed ID: 15148956
[TBL] [Abstract][Full Text] [Related]
32. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
Khan MA; Nasti TH; Owais M
J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
[TBL] [Abstract][Full Text] [Related]
33. Treatment of invasive fungal sinusitis with liposomal amphotericin B: a report of four cases.
Sungkanuparph S; Sathapatayavongs B; Kunachak S; Luxameechanporn T; Cheewaruangroj W
J Med Assoc Thai; 2001 Apr; 84(4):593-601. PubMed ID: 11460976
[TBL] [Abstract][Full Text] [Related]
34. Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations.
Sundar S; Mehta H; Suresh AV; Singh SP; Rai M; Murray HW
Clin Infect Dis; 2004 Feb; 38(3):377-83. PubMed ID: 14727208
[TBL] [Abstract][Full Text] [Related]
35. Lipid formulations of amphotericin B.
Dix SP; Andriole VT
Curr Clin Top Infect Dis; 2000; 20():1-23. PubMed ID: 10943516
[TBL] [Abstract][Full Text] [Related]
36. Implementation of clinical practice policy on the continuous intravenous administration of amphotericin B deoxycholate.
Maharom P; Thamlikitkul V
J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S118-24. PubMed ID: 17718252
[TBL] [Abstract][Full Text] [Related]
37. Reversible dilated cardiomyopathy associated with amphotericin B treatment.
Moyssakis I; Vassilakopoulos TP; Sipsas NV; Perakis A; Petrou A; Kosmas N; Pangalis GA
Int J Antimicrob Agents; 2005 May; 25(5):444-7. PubMed ID: 15848302
[TBL] [Abstract][Full Text] [Related]
38. [Endogenous candida endophthalmitis in a drug dependent patient: intravenous therapy with liposome encapsulated amphotericin B].
Neppert B; Guthoff R; Heidemann HT
Klin Monbl Augenheilkd; 1992 Aug; 201(2):122-4. PubMed ID: 1434381
[TBL] [Abstract][Full Text] [Related]
39. Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.
Paterson DL; David K; Mrsic M; Cetkovsky P; Weng XH; Sterba J; Krivan G; Boskovic D; Lu M; Zhu LP;
J Antimicrob Chemother; 2008 Dec; 62(6):1392-400. PubMed ID: 18812423
[TBL] [Abstract][Full Text] [Related]
40. [Cyanotic Raynaud phenomenon as a side effect of Amphotericin B].
Zernikow B; Fleischack G; Hasan C; Bode U
Klin Padiatr; 1996; 208(2):53-5. PubMed ID: 8901182
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
